PUNTA GORDA, Florida–Florida is scheduled to receive 4,000 doses of a monoclonal antibody treatment that the U.S. Food and Drug Administration (FDA) has found to be effective against the omicron variant that is derived from COVID-19. On Feb. 11,  the FDA sent a letter to Eli Lily, the maker of Bebtelovimab, that the company has its approval for an Emergency Use Authorization (EUA) to treat mild to moderate COVID-19 in adults and pediatric patients, age 12 years and up. The Florida Department of Health met with Health and Human Services (HHS) on Feb. 15, to discuss the number of doses that Florida would receive and, so far, that number is 4,000. Of the total 600,000 doses initially ordered by HHS, no one on the federal or state level will confirm whether these doses have been shipped or received. The same schedule for distribution  is expected to be in effect as …